OOIR: Observatory of International Research

Papers

(The median citation count of Gastroenterology is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Refractory Constipation in a 53-Year-Old Man	1657
Table of Contents	561
False-positive Fecal Immunochemical Tests in Users of New Anticoagulants	552
Cover 1	494
Underwater Endoscopic Mucosal Resection for Colorectal Lesions: A Bridge Between Conventional Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection	471
AGA Technical Review on Coagulation in Cirrhosis	448
CME Exam 2: Opioid Exposure Differentially Impacts Esophageal Body Contraction Over the Lower Esophageal Sphincter	416
Table of Contents	369
Iron Deficiency Anemia and Hematochezia Are Red Flags for Colorectal Cancer in Young Patients	358
Moderate Fluid Resuscitation Is Preferable in Acute Pancreatitis	342
Nausea, Vomiting, and Abdominal Distention After Atrial Fibrillation Therapy	327
Famotidine and Mortality in Coronavirus Disease 2019	308
The Revised REACH-B Model Predicts Hepatocellular Carcinoma in Patients With Chronic Hepatitis B	271
The Hardy side of H. pylori: uncovering ancient adaptations and host interactions	265
An Unusual Cause of Acute Liver Failure Diagnosed on Organ Explant in a Patient With Ulcerative Colitis	263
Beware: A Rare Pathogen Associated With Underlying Gastrointestinal Cancer	228
Host-Microbial Battle for Iron: New Opportunities to Combat Infection?	211
Elsewhere in The AGA Journals	188
Multiple Strictures of Small Intestine: Is It Crohn’s Disease?	188
How Can We Better Understand the Gastric Carcinogenesis of Helicobacter pylori?	184
Liver Health: An Emerging Concept	182
VEDOLIZUMAB FOR REFRACTORY MICROSCOPIC COLITIS: A CASE SERIES	181
THE IMPACT OF CARDIAC ARRHYTHMIAS ON INFLAMMATORY BOWEL DISEASE (IBD)	176
EQUIVALENT ADVERSE OUTCOMES FOR HOME AND HOSPITAL-BASED INFUSIONS OF INFLIXIMAB IN CHILDREN AND ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE	175
TOFACITINIB TREATMENT PREVENTS POST-OPERATIVE RECURRENCE OF CROHN’S DISEASE MODELED BY ILEOCECAL RESECTION IN HLA-B27 TRANSGENIC RATS	169

UTILITY OF FIBROSCAN IN ULCERATIVE COLITIS?	164
SAFETY AND EFFECTIVENESS OF THE BNT162B2 MRNA COVID-19 VACCINE IN A NATIONWIDE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE	163
EFFICACY OF BIOLOGIC DRUGS IN SHORT-DURATION VERSUS LONG-DURATION INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND INDVIDUAL-PATIENT-DATA METANALYSIS OF RANDOMIZED CONTROLLED TRIALS	163
A QUALITATIVE STUDY EXPLORING MEANINGFUL IMPROVEMENT IN BOWEL URGENCY AMONG ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	162
CORRELATION OF PUCAI BETWEEN MAYO ENDOSCOPIC AND GEBOES PATHOLOGY SCORES IN ASSESSING DISEASE ACTIVITY OF PEDIATRIC PATIENTS WITH UC AMONG HISPANICS AND NON-HISPANICS	160
OXPHOS DRIVES CRYPT FISSIONING REQUIRED FOR HEALING OF IBD ULCERS	159
TOWARDS A COMMON VALIDATED METHODOLOGY FOR HISTOLOGIC MEASUREMENT OF MUCOSAL HEALING IN ULCERATIVE COLITIS: INTRODUCING A NEW PROJECT OF THE BIOMARKERS CONSORTIUM OF THE FOUNDATION FOR THE NIH	159
EICOSATETRAYNOIC ACID REGULATES MITOCHONDRIAL AND EXTRA-CELLULAR MATRIX GENE EXPRESSION AND TISSUE STIFFNESS IN A HUMAN INTESTINAL ORGANOID MODEL OF ILEAL CROHN’S DISEASE	158
RELATIONSHIP BETWEEN SELF-REPORTED SLEEP AND DISEASE ACTIVITY DIFFERS BASED ON ENDOSCOPIC OR CLINICAL DISEASE ACTIVITY MEASURES	156
THE MICROBIAL LANDSCAPE OF ULCERATIVE COLITIS IN ENDOSCOPIC REMISSION	152
ADHERENT-INVASIVE E. COLI PROMOTE ER STRESS TO SUPPORT IL23R-DRIVEN AGR2-DEPENDENT ILEOCOLITIS	146
CURRENT VENOUS THROMBOEMBOLISM CHEMOPROPHYLAXIS PRACTICES AFTER SURGERY FOR IBD: SAVES-IBD TRIAL INITIAL REPORT	146
COMPARING THE GUT METABOLOMIC PROFILES IN HISPANIC AND NON-HISPANIC PEDIATRIC ULCERATIVE COLITIS PATIENTS	145
EPITHELIAL DUOX2 ACTIVATION INCREASES GUT PERMEABILITY AND BACTERIAL TRANSLOCATION THAT IS RESCUED WITH BUTYRATE SUPPLEMENTATION	145
PATIENTS' PERSPECTIVES, EXPERIENCES, AND CONCERNS WITH CROHN'S PERIANAL FISTULAE: INSIGHTS FROM SOCIAL MEDIA PLATFORMS	141
KLEBSIELLA PNEUMONIAE IN THE COLONIC MUCUS LAYER INFLUENCES CLOSTRIDIODES DIFFICILE PATHOGENESIS	135
THE CROHN'S AND COLITIS DISTRESS SCALE: ASSESSING THE DOMAINS OF IMPACT IN YOUTH WITH IBD	135
PEOPLE WITH IBD WANT TO TALK ABOUT SLEEP: RECOMMENDATIONS ON WHAT TO ASK AND HOW TO RESPOND TO SLEEP COMPLAINTS	135
CANNABINOID MEDICINAL CHEMISTRY HAS VAST IMPACT ON PHARMACOLOGY IN MOUSE AND RAT MODELS OF INFLAMMATORY BOWEL DISEASE (IBD)	134
EXIT INTERVIEWS EXPLORING PATIENTS’ EXPERIENCE OF CHANGES IN THEIR ABDOMINAL PAIN DURING THE PHASE 3 CLINICAL TRIAL OF MIRIKIZUMAB FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE	133
VEDOLIZUMAB REDUCES DENDRITIC, NOT MEMORY T CELLS, IN THE COLON, BUT ITS FAILURE IS NOT ASSOCIATED WITH LOW INTEGRIN OCCUPANCY ON DENDRITIC CELLS IN THE BLOOD	133
BIOLOGIC TREATMENT DE-ESCALATION IN PATIENTS WITH CROHN’S DISEASE IS COMMON IN THE UNITED STATES	131
CLINICAL OUTCOMES FOR EOSINOPHILIC ESOPHAGITIS AMONG CHILDREN AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE	131
CARE OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE WITH INADEQUATE RESPONSE OR INTOLERANCE TO UPADACITINIB: WHAT TO DO NEXT?	130
MACROPHAGE VITAMIN D RECEPTOR DEFICIENCY IMPAIRS MITOCHONDRIAL FUNCTION AND WEAKENS HOST DEFENSE AGAINST CANDIDA ALBICANS-RELATED INFLAMMATION	128
CHARACTERIZING LATE-ONSET CROHN’S DISEASE: INSIGHTS FROM A RETROSPECTIVE COHORT STUDY	126
EPITHELIAL PURINERGIC RECEPTORS ARE DOWNREGULATED IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE	126
INITIAL DEVELOPMENT AND VALIDATION OF A DISEASE-SPECIFIC RESILIENCE MEASURE FOR INFLAMMATORY BOWEL DISEASE: THE RISE-IBD INSTRUMENT	125
COMPARATIVE RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH VEDOLIZUMAB VS USTEKINUMAB IN OLDER ADULTS WITH INFLAMMATORY BOWEL DISEASE: A PROPENSITY-MATCHED COHORT ANALYSIS	122
DEFINING H2S EFFECTS USING SELECTIVE CYSTEINE UPTAKE MUTANT OF CROHN’S DISEASE DERIVED ADHERENT INVASIVE E. COLI	122
REGIONAL AND RACIAL DISPARITIES IN ULCERATIVE COLITIS AND CHOLANGIOCARCINOMA RELATED MORTALITY IN THE UNITED STATES AND TEXAS: A 21 YEAR OBSERVATIONAL STUDY	121
GUT-ASSOCIATED LYMPHOID TISSUE ATTRITION ASSOCIATES WITH RESPONSE TO ANTI-α4β7 THERAPY IN ULCERATIVE COLITIS	120
IMPACT OF INFLAMMATORY BOWEL DISEASE ON QUALITY OF LIFE AND FATIGUE: A SYSTEMATIC REVIEW AND META-ANALYSIS	119
ASSESSING THE PREVALENCE OF AVOIDANT RESTRICTIVE FOOD INTAKE DISORDER (ARFID) IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE (IBD)	118
TOBACCO AND INFLAMMATORY BOWEL DISEASE: AN IN-DEPTH EXAMINATION OF NATIONAL HOSPITAL OUTCOMES, ILLUMINATING DISTINCT EFFECTS IN ULCERATIVE COLITIS AND CROHN’S DISEASE IN THE UNITED STATES	117
EFFICACY AND SAFETY OF UPADACITINIB FOR ACUTE SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS	117
THE TNF SUPERFAMILY FACTOR TWEAK PROMOTES TRAINED IMMUNITY ASSOCIATED WITH PERSISTENT HISTONE MODIFICATIONS IN INTESTINAL FIBROBLASTS	116
DISTINCT MUCIN PROFILES CORRELATE WITH INFLAMMATION IN ULCERATIVE COLITIS	115
VEDOLIZUMAB PLUS CURCUMIN-QINGDAI FOR PATIENTS WITH ULCERATIVE COLITIS	113
ENHANCED ANTIOXIDANT SIGNALING BY MITOCHONDRIAL-TARGETED DRUG AUPHOS DRIVES ATTENUATION OF COLITIS	112
ORBITAL MYOSITIS AS AN EXTRAINTESTINAL MANIFESTATION OF IBD	111
ENTEROENDOCRINE CELLS REGULATE BARRIER INTEGRITY AND PROTECT AGAINST DSS-INDUCED OUTCOMES	111
CHARACTERIZATION OF THE JAK INHIBITORS TOFACITINIB AND UPADACITINIB IN HUMAN PRIMARY CELL 3D MODELS OF CROHN’S DISEASE AND ULCERATIVE COLITIS	109
A Surprise in the Spleen in a Young Woman	108
Determining the Endoscopic Follow-Up for Gastric Ulcers Based Upon Endoscopic Appearance and Histology (Poster Presentation)	106
Low Use of First-Line Agents for Constipation by Primary Care Providers in Patients Referred to Gastroenterology Clinic for Chronic Constipation	105
Single Center Study for Improving Hepatitis A & B Immunity in Veterans With Cirrhosis	104
Intrahepatic Bile Duct Foreign Body With Cholangitis After Pylorus-preserving Pancreatoduodenectomy: Is It a Fish Bone?	104
A Rare Cause of Confluent Abnormal Esophageal Mucosa	103
CME Exam 1: Pathology Out of Place	102

Upadacitinib: The New Jak Inhibitor in Town	102
Prandial Diarrhea: A Rare Late Complication After Percutaneous Endoscopic Gastrostomy With Jejunal Extension Tube Placement	101
An Unusual Cause of Chronic Pancreatitis in a Patient With Crohn’s Disease	101
Aldehyde “Adduction” Explains Synergy of Smoking and Alcohol in Promoting Pancreatitis	101
Elsewhere in The AGA Journals	100
CME Exam 1: A Systematic Review and Meta-analysis of Dietary Interventions Modulating Gut Microbiota and Cardiometabolic Diseases–Striving for New Standards in Microbiome Studies	99
EP1050: PREDICTION OF GASTROINTESTINAL TRACT CANCERS USING LONGITUDINAL ELECTRONIC HEALTH RECORD DATA	98
Information for Authors and Readers	98
AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity	98
Prevalence and Predictors of Young-Onset Colorectal Neoplasia: Insights From a Nationally Representative Colonoscopy Registry	98
Qualitive Improvement Initiative to Eliminate Inpatient Fecal Occult Blood Testing	98
Liver Transplantation for Colorectal Cancer Metastasis: An Evolving Option With Hope in Selected Patients	97
Cover 1	96
Evolutionary Medicine for Chronic Inflammatory Diseases of the Gut: More Than a Clinical Fantasy?	96
Sucrase Isomaltase Dysfunction Reduces Sucrose Intake in Mice and Humans	95
Fazirsiran Unveiled: Methodological Considerations for Optimizing Treatment in Alpha-1 Antitrypsin Deficiency	95
A Rare Cause of Blood in Stool and Anemia	94
A Concerning Case of Severe Gastritis With Gastrointestinal Protein Loss	94
The MODY-Causing Mutation of the Human Carboxyl Ester Lipase Gene (CEL) Triggers Chronic Pancreatitis but not Diabetes in Mice	93
Names Matter: A Call to Neurogastroenterologists to Examine How We Can Improve the Nomenclature We Use to Describe the Disorders Our Patients Experience	92
Factor Analysis of the Rome IV Criteria for Major Disorders of Gut-Brain Interaction (DGBI) Globally and Across Geographical, Sex, and Age Groups	91
Beyond Clinical Accuracy: Considerations for the Use of Generative Artificial Intelligence Models in Gastrointestinal Care	90
MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells	90
Toward the Understanding of Altered Gut Microbiome in Crohn’s Disease: Cause or Consequence	89
Interventions to Increase Follow-Up of Abnormal Stool-Based Colorectal Cancer Screening Tests in Safety Net Settings: A Systematic Review	89
Su1423: CYCLIC VOMITING SYNDROME IN A HISPANIC COHORT: COMPARISON OF DEMOGRAPHICS, COMORBIDITIES, MEDICATION PRESCRIPTIONS, AND THE POSSIBLE ROLE OF CANNABIS WITH NON-HISPANICS	88
Association Between Famotidine Use and COVID-19 Severity in Hong Kong: A Territory-wide Study	88
Odevixibat Treatment Induces Biliary Bile Acid Secretion in Responsive Patients With Bile Salt Export Pump Deficiency	88
A Novel, IBS-Specific IgG ELISA-Based Elimination Diet in Irritable Bowel Syndrome: A Randomized, Sham-Controlled Trial	87
Mo1623 NATURAL HISTORY OF CYCLIC VOMITING SYNDROME IN ADULT PATIENTS FROM THE UNITED STATES: RESULTS FROM A 6-MONTH OBSERVATIONAL LONGITUDINAL STUDY	87
Controversy of Preoperative Exposure to Tumor Necrosis Factor Inhibitors in Surgical and Infectious Complications of Inflammatory Bowel Disease	87
The Rise of Aptamers: Promising Avenues in the Treatment of Solid Tumors	86
Reply	86
Recurrent Epistaxis and Diffuse Hepatic and Splenic Vascular Malformations	84
Cirrhosis and Portal Hypertension in Compound Heterozygous People With Cystic Fibrosis Harboring One F508del CFTR Gene Mutation	83
Information for Authors and Readers	83
132 EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE	83
Elsewhere in The AGA Journals	83
Assessing Risk for Gastrointestinal Cancers: Forewarned Is Forearmed…˙	83
Reply	82
Spotlight	82
Table of Contents	82
Exam 1: A Case of Multiple Adenomatous Colon Polyps and Meningiomas	82
Incidence and Prediction of Unrelated Mortality After Successful Endoscopic Eradication Therapy for Barrett’s Neoplasia	81
Balancing the Tradeoffs Between Office and Video Doctor Visits	80
The Economic Iceberg of Celiac Disease: More Than the Cost of Gluten-Free Food	79
Risk of Venous Thromboembolism Among Patients With Inflammatory Bowel Disease Who Contract Severe Acute Respiratory Syndrome Coronavirus 2	78
Case Finding for the Pale Celiac Patient: New Iron Deficiency Anemia Guidelines Missing Many Anemic Celiacs?	78
Table of Contents	78
Building Your Professional Brand: Tips for Early Career Faculty	77
713f Histologic Activity in Ulcerative Colitis Patients Achieving Endoscopic Healing is Associated with Higher Rate of Relapse and a Distinct Mucosal Microbial and Transcriptional Profile	77
Understanding Early-Onset Colorectal Cancer: The Role of Obesity	77
Elsewhere in The AGA Journals (Preview Section)	77
Hacking Death in Dublin	77
713e Longitudinal Analysis in A HNF4AΔIEC Mouse Colitis Model Reveals that Preclinical Flaring is Associated with Increased Akkermansia muciniphila Levels in the Gut Microbiome	77
MACHINE LEARNING-BASED PREDICTION OF GEBOES SCORE AND HISTOLOGIC IMPROVEMENT AND REMISSION THRESHOLDS IN ULCERATIVE COLITIS	76
EVALUATION OF CLINICAL VARIABLES, RADIOLOGICAL VISUAL ANALOG SCORING, AND RADIOMICS FEATURES ON CT ENTEROGRAPHY FOR CHARACTERIZING SEVERE INFLAMMATION AND FIBROSIS IN STRICTURING CROHN’S DISEASE	76
LONGITUDINAL MONITORING OF INFLAMMATORY BOWEL DISEASE ACTIVITY USING WEARABLE DEVICES THROUGH INFLAMMATORY MARKERS IN SWEAT	76
SMOKING IS NOT AN INDEPENDENT RISK FACTOR FOR SURGERY IN PATIENTS WITH CROHN'S DISEASE ON BIOLOGIC THERAPY	75
ACCELERATED INFLIXIMAB INFUSION SAFETY AND TOLERABILITY IS NON-INFERIOR TO STANDARD INFUSION PROTOCOL IN INFLAMMATORY BOWEL DISEASE PATIENTS – A RANDOMIZED CONTROLLED STUDY	74
MODELING THE TRANSITION TO THE FOURTH EPIDEMIOLOGIC STAGE OF INFLAMMATORY BOWEL DISEASE: PREVALENCE EQUILIBRIUM	74
TRANSFER RNA MODIFICATION CONTRIBUTE TO PATHOGENESIS OF INTESTINAL INFLAMMATION BY ALTERING EPITHELIAL BARRIERS	74
DEVELOPMENT OF NANOPARTICLE-ENCAPSULATED BRD4 INHIBITORS FOR NOVEL EPIGENETIC THERAPEUTICS OF IBD	74
UNRAVELING THE CONNECTION: RACIAL INFLUENCE ON THE DEVELOPMENT OF ULCERATIVE COLITIS AFTER BARIATRIC SURGERY	74
INFLIXIMAB MARKET SHARE AND ASSOCIATED COST SAVINGS FOLLOWING BIOSIMILAR MARKET ENTRY	73
IMPROVEMENT IN GROWTH AND NUTRITION STATUS AFTER ANTI-TNF THERAPY INITIATION AMONG PATIENTS WITH PEDIATRIC CROHN’S DISEASE: RESULTS FROM THE COMBINE TRIAL	72
DIFFERENTIAL MORTALITY OUTCOMES AMONG DIFFERENT CLASSES OF DRUGS IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS USING A MULTI-CENTER RESEARCH NETWORK	72
A NOVEL BISPECIFIC CD8 TREG MODULATOR TARGETING CYTOLYTIC CD8 REGULATORY T CELLS REDUCES PATHOGENIC CD4 T CELLS AND INFLAMMATION IN TRANSLATIONAL MODELS OF INTESTINAL AUTOIMMUNE AND INFLAMMATORY DISEA	72
DECIPHERING THE BURDEN OF INFLAMMATORY BOWEL DISEASE LANDSCAPE (1990-2019) IN HIGH INCOME NORTH AMERICA: PROJECTIONS, TEMPORAL SHIFTS, AND A GLIMPSE BEYOND TO 2040	72
MOOD DISORDERS AND OUTCOMES OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES: A 2016-2019 NATIONWIDE ANALYSIS	71
THE IMPACT OF INFLAMMATORY BOWEL DISEASES ON THE OUTCOMES OF PATIENTS ADMITTED WITH ACUTE VIRAL HEPATITIS: A 2016-2019 NATIONWIDE ANALYSIS	71
QUANTITATIVE AND EXPLAINABLE ARTIFICIAL INTELLIGENCE (AI)-POWERED APPROACHES TO PREDICT ULCERATIVE COLITIS DISEASE ACTIVITY FROM HEMATOXYLIN AND EOSIN (H&E)-STAINED WHOLE SLIDE IMAGES (WSI)	71
EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD AND LIBERTY-UC STUDY	70
SYSTEMATIC REVIEW WITH META-ANALYSIS: SAFETY AND EFFICTIVENESS OF COMBINING BIOLOGICS AND SMALL MOLECULES IN INFLMAMMATORY BOWEL DISEASE	70
INTESTINAL PERFORATIONS IN PATIENTS WITH IBD: AN ANALYSIS OF THE NATIONAL INPATIENT SAMPLE 2015-2019	69
MANAGEMENT STRATEGIES FOR OBESITY VARY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE	69
MULTIPLE ENVIRONMENTAL AND SOCIAL DETERMINANTS OF HEALTH FACTORS WERE NOT ASSOCIATED WITH THE GASTROINTESTINAL SYMPTOMATIC BURDEN OF ULCERATIVE COLITIS WITH MUCOSAL HEALING	69
TELEHEALTH ENHANCES RETENTION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE WITHIN A TERTIARY CARE INFLAMMATORY BOWEL DISEASE CENTER	69
COMPARATIVE ASSESSMENT OF BIOBANK DATASETS FOR THE STUDY OF INFLAMMATORY BOWEL DISEASE	68
A NEW MODEL TO STUDY INTESTINAL FIBROSIS USING IPSC-DERIVED HUMAN EPITHELIAL AND MESENCHYMAL CELLS FROM CROHN’S DISEASE PATIENTS	68

CREATINE KINASE EXPRESSION IS PROTECTIVE IN A MOUSE COLITIS MODEL	67
COST-DRIVERS OF HEALTHCARE EXPENDITURES IN INFLAMMATORY BOWEL DISEASE	67
MRI AND BLOOD-BASED BIOMARKERS ASSOCIATED WITH SURGICAL MANAGEMENT IN CHILDREN AND ADULTS WITH SMALL BOWEL CROHN'S DISEASE	67
GUT MICROBIAL METABOLISM OF 5-ASA IS PROSPECTIVELY ASSOCIATED WITH TREATMENT FAILURE IN PATIENTS WITH IBD	66
TREATMENT PREFERENCES IN CROHN’S DISEASE PERIANAL FISTULA: PERSPECTIVES OF HEALTHCARE PROFESSIONALS	65
REAL WORLD EFFECTIVENESS OF JAK INHIBITOR UPADACITINIB IN ULCERATIVE COLITIS VERSUS CROHN’S DISEASE IN AN IBD TERTIARY CARE CENTER.	65
ERYTHEMA NODOSUM AND PYODERMA GANGRENOSUM IN PEDIATRIC INFLAMMATORY BOWEL DISEASE	65
PREVALENCE OF FRAILTY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. A PILOT STUDY.	65
COMMENSAL GUT BACTERIA REGULATE HIF ACTIVITY TO PROMOTE INTESTINAL HOMEOSTASIS	65
DEVELOPMENT OF CROHN'S DISEASE IN PATIENT PRESENTING WITH COMPLEX PERIANAL FISTULA TO A TERTIARY MEDICAL CARE CENTER	65
UTILITY OF PR3-ANCA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS	65
VEDOLIZUMAB RESPONSE AND NON-RESPONSE IN ULCERATIVE COLITIS: INSIGHTS FROM SPATIAL TRANSCRIPTOMICS	64
EVALUATION OF THE CLINICAL STAGE FXR AGONIST FXR314 IN HUMAN PRIMARY CELL 3D MODELS OF CROHN’S DISEASE AND ULCERATIVE COLITIS	64
EXPLORING FACTORS ASSOCIATED WITH SEROLOGICAL RESPONSE TO SARS-COV-2 VACCINES IN INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE: INTERACTIVE VISUALIZATION METHODS FOR MULTIDIMENSIONAL DATA	64
CHANGING THERAPY TO ACHIEVE ENDOSCOPIC HEALING IN ASYMPTOMATIC PATIENTS WITH IBD: WHEN IS PERFECT THE ENEMY OF GOOD?	64
COST PER REMISSION FOR MIRIKIZUMAB VS USTEKINUMAB IN THE MAINTENANCE PHASE FOR MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS TREATMENT FROM THE UNITED STATES COMMERCIAL PAYER PERSPECTIVE	64
DEVELOPING A SCORING SYSTEM TO PREDICT CHRONIC OPIOID USE AMONG ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE	63
HEALTH INSURANCE KNOWLEDGE AND HEALTH INSURANCE SELF-EFFICACY IN ADOLESCENTS AND YOUNG ADULTS WITH IBD	63
THE FUNCTION OF THE CYSTATHIONINE-GAMMA-LYASE/HYDROGEN SULFIDE AXIS IN THE PATHOGENESIS OF ULCERATIVE COLITIS	63
BACTERIAL SPHINGOLIPIDS EXACERBATE COLITIS BY INHIBITING ILC3-DERIVED IL-22 PRODUCTION	62
BIOLOGICS AND SMALL MOLECULES USED IN IBD MIMICS: HIGHLIGHTING THE IMPORTANCE OF DIAGNOSIS CONFIRMATION	62
FIBER-DEFICIENT DIET INHIBITS COLITIS THROUGH REGULATION OF THE NICHE AND METABOLISM OF A GUT PATHOBIONT	61
THE RELATIONSHIP BETWEEN SELF-REPORTED SLEEP, WRIST ACTIGRAPHY, AND SYMPTOMS AMONG ADULTS WITH INFLAMMATORY BOWEL DISEASE (IBD)	61
MITOCHONDRIAL TURNOVER IS ELEVATED IN RESPONSE TO INTESTINAL INFLAMMATION AND IS AMENABLE TO THERAPUTIC TARGETING VIA UROLITHIN A	61
UPADACITINIB RESOLVES DIARRHEA AND FECAL CALPROTECTIN ABNORMALITIES IN BUDESONIDE-DEPENDENT MICROSCOPIC COLITIS	61
SOCIALLY VULNERABLE PATIENTS WITH INFLAMMATORY BOWEL DISEASE ARE AT INCREASED RISK FOR VACCINE PREVENTABLE ILLNESS	61
PROTEOLYSIS TARGETING CHIMERAS (PROTACS) AS ATTRACTIVE THERAPEUTICS IN IBD THROUGH THE REGULATION OF HYPOXIA-INDUCIBLE FACTORS	61
UNIQUE MONOCYTE EXPRESSION SIGNATURE IN A STXBP2 MUTATION CAUSING INFANTILE ONSET VEO-IBD AND HLH	60
Measuring the Quality and Safety of Upper Endoscopy in Patients Taking Glucagon-like Peptide 1 Receptor Agonists	60
VEDOLIZUMAB DOES NOT ALTER IMMUNOGLOBULIN LEVELS IN BREASTMILK OF MOTHERS WITH IBD	60
NON-MEDICAL SWITCHING FROM INFLIXIMAB TO A BIOSIMILAR IN ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE	60
EFFICACY OF UPADACITINIB IN PATIENTS PREVIOUSLY TREATED WITH TOFACITINIB FOR THE MANAGEMENT OF ULCERATIVE COLITIS	60
Treating Chronic Pancreatitis Pain With the Use of Extracorporeal Shock-Wave Lithotripsy and Endoscopy	60
Focus on Psychological Intervention: Insights From Thoracoabdominal Wall Motion–Guided Biofeedback Treatment of Abdominal Distention	59
Elsewhere in The AGA Journals (Preview Section)	59
Reply	59
Table of Contents	59
Corrigendum	58
Endoscopic Transpapillary Gallbladder Stenting Prevents Recurrent Cholecystitis: Are the Benefits the Same in Patients With or Without Common Bile Duct Stones?	58
Reply	58
Cover 1	57
The New Horizon of Clostridioides difficile Infection Treatment	57
Re-evaluating Confounders and Risk Interpretation in FIT-Positive Cancer Screening	57
Shining a New Light on Gastrointestinal Endoscopy: Evaluating the Effect of Green Light Versus Dim Light on Performance in the Endoscopy Suite	57
An Invisible Threat	57
Pigmented Polypoid Lesion in a 24-Year-Old Woman With Hematochezia	56
A Young Woman With Recurrent Rectal Bleeding	56
Efficacy of Drugs Acting on Histamine 1 Receptors in Irritable Bowel Syndrome: Systematic Review and Meta-Analysis	55
775f The Introduction of Faecal Immunochemical Testing as a Triaging Tool for Colorectal Cancer Investigation During the COVID-19 Pandemic. A Service Evaluation and Report.	55
CME Exam 1: An Unusual Case of Cardiac Involvement in Crohn’s Disease	55
Unusual White Esophageal Patches With Cobblestone Appearance	55
The Noticeable Crosslink between miR-122 and Metabolic Dysfunction	55
An Atypical Cause of Musculoskeletal Pain in a Patient With Chronic Inflammatory Bowel Disease	55
867 SUBSETS OF CX3CR1-POSITIVE GASTRIC MUSCULARIS PROPRIA MACROPHAGES HAVE DIFFERENT FATES FOLLOWING INDUCTION OF DIABETES	54
Sa1260: EVALUATION OF QUALITATIVE LATERAL FLOW IMMUNOASSAY FOR DETECTING GLUTEN IMMUNOGENIC PEPTIDES IN CELIAC PATIENTS FOLLOWING A HABITUAL GLUTEN-FREE DIET.	54
875 RISK OF METACHRONOUS ADVANCED NEOPLASIA AFTER ADENOMA DETECTION IN PATIENTS AGED 40-49 YEARS COMPARED TO PATIENTS AGED 50-59 YEARS	54
Su052 DEVELOPMENT AND TEMPORAL VALIDATION OF A PREDICTION MODEL FOR RISK-STRATIFIED FIT COLORECTAL CANCER SCREENING	54
863 VALIDATION OF TOOLS FOR PREDICTING INCIDENT ADENOCARCINOMA OF THE ESOPHAGUS OR ESOPHAGOGASTRIC JUNCTION	54
872 PREVALENCE OF EARLY-AGE ONSET COLORECTAL NEOPLASIA IN AVERAGE RISK INDIVIDUALS UNDERGOING SCREENING COLONOSCOPY: A SYSTEMATIC REVIEW AND META-ANALYSIS	54
854 RISK OF IMMUNOGENICITY TO A SUBSEQUENT THERAPY IS THE HIGHEST DURING THE FIRST YEAR AFTER A SWITCH IN THERAPY IN IMMUNOGENIC PATIENTS WITH INFLAMMATORY BOWEL DISEASES	54
Su057 A BAYESIAN JOINT POLYP PROFILE MODEL FOR THE LONGITUDINAL DEVELOPMENT OF ADVANCED ADENOMAS THAT INCORPORATES A PATIENT'S ENTIRE HISTORY OF POLYP-SPECIFIC DATA	54
Mo1240: NOVEL EXOSOMAL MICRORNAS SPECIFIC FOR PANCREATIC DUCTAL ADENOCARCINOMA IDENTIFIED FROM PANCREATIC JUICE	53
Sa1272: SEROPREVALENCE OF CELIAC DISEASE (CD) IN MEXICAN MESTIZO PATIENTS WITH AUTOIMMUNE THYROID DISEASE (ATD).	53
Sa1271: PATIENTS WITH CELIAC DISEASE HAVE NO INCREASED RATE OF ADVERSE EVENTS AFTER COVID-19 VACCINE ADMINISTRATION COMPARED WITH NON-CELIAC CONTROLS	53
EP1318: THE USE OF INTRAVENOUS IMMUNOGLOBULIN FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE REFRACTORY TO OR WITH CONTRAINDICATIONS TO STANDARD THERAPIES	52
Sa1300: VENOUS THROMBOEMBOLISM IS COMMON IN PATIENTS WITH ACUTE NECROTIZING PANCREATITIS AND IS ASSOCIATED WITH WORSE CLINICAL OUTCOMES: RESULTS OF A MULTICENTER ELECTRONIC HEALTH RESEARCH NETWORK STU	51
Sa1275: ASSOCIATED FACTORS WITH ACUTE DIARRHEA IN SARS-COV-2 INFECTION: A CASE-CONTROL STUDY	51
Sa1270: PHYSICAL ACTIVITY LEVELS IN INDIVIDUALS WITH CELIAC DISEASE AND ASSOCIATIONS WITH PHYSICAL AND PSYCHOLOGICAL FACTORS.	51
EP1323: STW 5-II BENEFICIALLY MODULATES HUMAN GUT MICROBIOME IN VITRO	51
Fr002 EFFECT OF THE COVID-19 PANDEMIC ON ACUTE GASTROINTESTINAL BLEEDING	51
EP1327: GUT MICROBIOME SIGNATURES REFLECT DIFFERENT SUBTYPES OF IRRITABLE BOWEL SYNDROME	50
EP1326: ANTI-INFLAMMATORY EFFECT OF EXTRACELLULAR VESICLES ISOLATED FROM ROSEBURIA INTESTINALIS IN RAW264.7 CELL LINE	50
Sa1307: FACTORS ASSOCIATED WITH INCREASED LENGTH OF STAY IN PATIENTS WITH ACUTE NECROTIZING PANCREATITIS: A TERTIARY REFERRAL CENTER EXPERIENCE	50
EP1324: COVID-19: DIARRHEA, INFLAMMATION AND INTESTINAL MICROBIOTA	50
Sa1309: USEFULNESS OF THE NEW DIAGNOSTIC CRITERIA OF ACUTE NECROTIC COLLECTION COMBINING WITH REVISED ATLANTA CLASSIFICATION AND JAPANESE GUIDELINE	49
EP1334: EFFECTS OF THE EXTRACELLULAR VESICLES DERIVED FROM BLAUTIA OBEUM ON PARKINSON'S DISEASE	49
Fr005 SEVERE COVID-19 ASSOCIATED WITH INCREASED RISK OF GI BLEEDING DURING HOSPITALIZATION	49
Mo1252: TEMPORAL TRENDS OF CHRONIC PANCREATITIS IN BRAZIL FROM 2009-2019: A NATIONWIDE SAMPLE OF OVER 64,000 HOSPITALIZATIONS	49
Mo1250: INCIDENCE OF PANCREATIC CANCER WITHIN PANCREATIC CYSTIC NEOPLASM: 6-YEAR RESULTS FROM A NATIONWIDE PATHOLOGY DATABASE	48
Mo1255: METABOLOMIC ANALYSIS OF PANCREATIC CYST FLUID BY PROTON NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY	48
Fr016 MICROBIAL COLONIZATION SUPRESSES COLONIC ACE2 EXPRESSION	48
Mo1253: THE SURVEILLANCE OF INCIDENTALLY DETECTED PANCREATIC CYSTS IN COMMUNITY HOSPITALS INFREQUENTLY ADHERE TO GUIDELINES	48
Mo1258: EVALUATING THE IMPACT OF ENDOSCOPIC ULTRASOUND IN THE MULTIDISCIPLINARY MANAGEMENT OF PANCREATIC CYSTIC LESIONS: A NESTED, CASE CONTROL STUDY	48
Mo1315: MULTI-FACTORIAL ETIOLOGY OF GALLBLADDER CANCER: A USA CONTROL-CASE STUDY	47
Fr044 METACHRONOUS OUTCOMES IN PATIENTS WITH TRADITIONAL SERRATED ADENOMA AT BASELINE COLONOSCOPY	47
Sa1427: THE LONGTERM EFFECTS OF COVID-19 ON ELEVATED LIVER FUNCTION TESTS AND OUTCOMES	47
Sa1430: MELD-NA, ALBUMIN, AND AGE AS NOVEL PREDICTORS OF 1 YEAR MORTALITY IN CIRRHOTIC PATIENTS UNDERGOING ELECTIVE TIPS	47
EP1363: INTESTINAL ULTRASONOGRAPHY FOR INFLAMMATORY BOWEL DISEASE, SPECIFIC LIMITATIONS IN A PAEDIATRIC POINT OF CARE SETTING	47
Sa1366: BILIARY COMPLICATIONS IN LIVING DONORT LIVER TRANSPLANT: MATCHED COHORT STUDY IN A LARGE TERTIARY CARE CENTER	47
83: ACCURATE PREDICTION MODELING OF SIX-WEEK MORTALITY AMONG PATIENTS WITH CIRRHOSIS PRESENTING WITH PORTAL HYPERTENSIVE BLEEDING: CALIBRATION AND EXTERNAL VALIDATION USING A MULTI-CENTER U.S. COHORT	47
Sa1426: TRENDS ANALYSIS OF INPATIENT OUTCOMES IN PATIENTS WITH HEPATORENAL SYNDROME AND CONCOMITANT ALCOHOLIC OR NONALCOHOLIC CIRRHOSIS: A NATIONWIDE INPATIENT SAMPLE ANALYSIS	47
EP1365: CHITINASE 3-LIKE 1 LEVELS IN FECES BUT NOT URINE AS AN EMERGING BIOMARKER OF PEDIATRIC INFLAMMATORY BOWEL DISEASE	47
Mo1317: THE OUTCOMES OF PERCUTANEOUS VERSUS ENDOSCOPIC DRAINAGE IN PATENTS WITH HILAR CHOLANGIOCARCINOMA: A NATIONWIDE SAMPLE STUDY	46
Fr051 MODERATE CONCORDANCE BETWEEN TRAINEE SELF-ASSESSMENT AND EXPERT ASSESSMENT OF COLD SNARE POLYPECTOMY COMPETENCE: RESULTS FROM A RANDOMIZED CONTROLLED STUDY	46
90: UBC13-MEDIATED P62 UBIQUITINATION PROTECTS AGAINST NONALCOHOLIC STEATOHEPATITIS LINKED TO DEFECT IN MITOPHAGY	46